2Seventy Bio — Technical Presentation (May 2023)
64 slides from 2Seventy Bio's technical presentation, May 19, 2023
Slide 1: 2seventy R&D Deep Dive: ASGCT and Beyond
2seventy R&D Deep Dive: ASGCT and Beyond May 19, 2023
Slide 2: Cautionary note regarding forward-looking statements
Cautionary note regarding forward-looking statements These slides and the accompanying oral presentation may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to: statements about our plans,
Slide 3: Agenda and Vision
Agenda and Vision 3 Nick Leschly, chief kairos officer
Slide 4: The sole mission of 2seventy is to unleash the curative potential of the T cell
The sole mission of 2seventy is to “unleash the curative potential of the T cell” Our experience in drug development and deep execution capabilities in cell therapy allow us to design & deliver multi-layered, multi-modality T cell-based solutions that have the potential to address and overcome the i
Slide 5: 2seventy – At a Glance
2seventy – At a Glance ABECMA Commercial ABECMA Development BMS 50/50 US $297M 2022 / $470-570M 2023* Potential $2-3B US Peak 3rd Line K3 & FDA Submission Initiation of Front Line K9 ABECMA® Capacity Expansion Predictable Delivery ABECMA profitable in 2023** Cash runway into 2026** 425 employees Unl
Slide 6: Agenda
Agenda TOPIC SPEAKER Corporate Strategy and Vision ABECMA Clinical, Operational and Financial Progress Advances Across Pipeline and Internal DP Manufacturing AML Clinical and Preclinical Developments Ex Vivo and In Vivo Gene Editing Applications Wrap-Up and Questions Nick Leschly, chief kairos offic
Slide 7: ABECMA and R&D Financial Overview
ABECMA and R&D Financial Overview 7 Chip Baird, chief financial officer
Slide 8: ABECMA and Financial Overview: Four key takeaways
ABECMA and Financial Overview Four key takeaways… ABECMA continues to achieve strong revenue growth ABECMA is cash flow positive with improving margins ABECMA has an attractive and long-term commercial trajectory 2seventy is efficient with its R&D investment 1 2 3 4 8
Slide 9: WW Sales of CAR T Therapies by Quarter of Launch
$0 $25 $50 $75 $100 $125 $150 $175 $200 $225 $250 $275 $300 $325 $350 $375 $400 W W S a le s ( in m ill io n s ) Quarter(s) Following Approval WW Sales of CAR T Therapies, by Quarter of Launch Kymriah (Novartis) Yescarta (Gilead) Tecartus (Gilead) Breyanzi (BMS) ABECMA (BMS/2seventy) Carvykti (J&J/L
Slide 10: Strong start to 2023 for ABECMA
Strong start to 2023 for ABECMA May 2023 update •Cash flow positive in 1Q23 •On track to achieve upper end of $470-570M* revenue guidance •Second aLVV suite approved; on track for sLVV approval in 1H24 •Successful DP step-up complete; additional step- ups on track for 2023 •$200-300M of operating in
Slide 11: Real-world MM treatment decisions are practical and patient-driven
Real-world MM treatment decisions are practical and patient-driven Efficacy Potential for deep and durable response Safety Predictable and manageable side-effect profile Real World Experience Physician real-world experience with the product Availability Slot availability in the relevant time frame T
Slide 12: More than half of eligible patients will not have access to a CAR T in 2025
Assuming capacity growth in-line with CD-19 experience, more than half of eligible patients will not have access to a CAR T in 2025 12 2023 (5L+) 2024 (3L+) 2025 (3L+) * Illustrative US Multiple Myeloma CAR T Capacity Growth Scenario 37% CAR T capacity growth 37% CAR T capacity growth 2026-30 (label
Slide 13: Even with 100% annual growth, 50% of eligible patients will not receive CAR T
Even with 100% annual growth in commercial capacity, 50% of eligible patients will not be able to receive a CAR T in 2025 13 100% CAR T capacity growth 100% CAR T capacity growth * *Each figure = ~1,000 patients = RRMM patients treated with CAR T = not eligible for CAR T= RRMM patients eligible for
Slide 14: R&D Spend in Context
R&D Spend in Context Disciplined investment across the portfolio to drive innovation 1Q23 GAAP R&D Expense, as reported ($M) 100 85 80 18 67 66 62 13 38 33 50 44 TSVT gross TSVT net of collab. reimbursements SANA ATRAFATEALLO PSTXLEGNBEAM ACLX Ø 66 68 57 R&D as reported TSVT Net R&D (non-Abecma) TSV
Slide 15: Advances Across Pipeline and Internal DP Manufacturing
Advances Across Pipeline and Internal DP Manufacturing 15 Philip Gregory, D.Phil., chief scientific officer
Slide 16: 2seventy bio’s R&D philosophy
2seventy bio’s R&D philosophy Accelerate with Industry Leading Partnerships Identify the Key Problem Layer Innovations Learn Fast in the Clinic Understand tumor resistance Explore new biology Focus on the hard problem Define clear hypotheses Deploy our unique toolbox Deliver multi-nodal solutions 27
Slide 17: Our Innovation Ecosystem
BINDER TECHNOLOGIES ADVANCED SCREENING PROTEIN ENGINEERING TUMOR IMMUNOLOGY CAPABILITIES CAR TCR CCR DARIC megaTAL PLATFORM PROTEIN ENGINEERING CELL/DRUG PHARMACOLOGY MOLECULAR IMMUNOLOGY ENHANCED COSTIM REGULATED megaTAL PLATFORM PROTEIN ENGINEERING IN VIVO MODELING MOLECULAR IMMUNOLOGY TME BIOLOGI
Slide 18: Our Innovation Ecosystem: Solid Tumor Example MUC16
BINDER TECHNOLOGIES ADVANCED SCREENING PROTEIN ENGINEERING TUMOR IMMUNOLOGY CAPABILITIES CAR TCR CCR DARIC megaTAL PLATFORM PROTEIN ENGINEERING CELL/DRUG PHARMACOLOGY MOLECULAR IMMUNOLOGY ENHANCED COSTIM REGULATED megaTAL PLATFORM PROTEIN ENGINEERING IN VIVO MODELING MOLECULAR IMMUNOLOGY TME BIOLOGI
Slide 19: Our Innovation Ecosystem: Example SC-DARIC33
BINDER TECHNOLOGIES ADVANCED SCREENING PROTEIN ENGINEERING TUMOR IMMUNOLOGY CAPABILITIES CAR TCR CCR DARIC megaTAL PLATFORM PROTEIN ENGINEERING CELL/DRUG PHARMACOLOGY MOLECULAR IMMUNOLOGY ENHANCED COSTIM REGULATED megaTAL PLATFORM PROTEIN ENGINEERING IN VIVO MODELING MOLECULAR IMMUNOLOGY TME BIOLOGI
Slide 20: Our Innovation Ecosystem: Example NG-AML 27T32
BINDER TECHNOLOGIES ADVANCED SCREENING PROTEIN ENGINEERING TUMOR IMMUNOLOGY CAPABILITIES CAR TCR CCR DARIC megaTAL PLATFORM PROTEIN ENGINEERING CELL/DRUG PHARMACOLOGY MOLECULAR IMMUNOLOGY ENHANCED COSTIM REGULATED megaTAL PLATFORM PROTEIN ENGINEERING IN VIVO MODELING MOLECULAR IMMUNOLOGY TME BIOLOGI
Slide 21: New in-house manufacturing facility (270-MPH)
2seventy bio’s NEW in-house manufacturing facility (270-MPH) The heart of our translational cell therapy engine - Enable Fully Integrated Translational Cell Therapy Platform Enables manufacture and release of drug product for multiple Phase I clinical trials Co-located @ 60 Binney with research, PD
Slide 22: Pipeline by indication and development stage
INDICATION [DRUG] TARGET TECHNOLOGY DISCOVERY STAGE R&D IND-ENABLING PRECLINICAL STUDIES CLINICAL STUDIES APPROVED PRODUCTS Multiple Myeloma [ABECMA] BCMA CAR T cell Multiple Myeloma [ABECMA] BCMA CAR T cell AML-Pediatric [SC-DARIC33] CD33 Drug-Regulated; CAR T cell (DARIC) B-NHL [bbT369] CD79a CD20
Slide 23: Pipeline by indication and development stage
INDICATION [DRUG] TARGET TECHNOLOGY DISCOVERY STAGE R&D IND-ENABLING PRECLINICAL STUDIES CLINICAL STUDIES APPROVED PRODUCTS Multiple Myeloma [ABECMA] BCMA CAR T cell Multiple Myeloma [ABECMA] BCMA CAR T cell AML-Pediatric [SC-DARIC33] CD33 Drug-Regulated; CAR T cell (DARIC) B-NHL [bbT369] CD79a CD20
Slide 24: Pipeline by indication and development stage
INDICATION [DRUG] TARGET TECHNOLOGY DISCOVERY STAGE R&D IND-ENABLING PRECLINICAL STUDIES CLINICAL STUDIES APPROVED PRODUCTS Multiple Myeloma [ABECMA] BCMA CAR T cell Multiple Myeloma [ABECMA] BCMA CAR T cell AML-Pediatric [SC-DARIC33] CD33 Drug-Regulated; CAR T cell (DARIC) B-NHL [bbT369] CD79a CD20
Slide 25: What you will hear today
What you will hear today Clinical progress with SC-DARIC33 in patients with AML 2seventy bio’s NextGen AML approach…. packed with innovation First regulatable CAR T cell data from the clinical trial* Key questions we will address: • Initial safety and tolerability? • Can we dose RAPA to target level
Slide 26: AML Clinical and Preclinical Developments
AML Clinical and Preclinical Developments 26 Steve Bernstein, M.D., chief medical officer Steve Shamah, Ph.D., SVP, oncology research
Slide 27: Acute Myeloid Leukemia is a devastating disease in need of new approaches
Acute Myeloid Leukemia is a devastating disease in desperate need of new therapeutic approaches A normal bone marrow making WBC, RBC and platelets A leukemic bone marrow packed with blasts preventing normal blood cell formation 27
Slide 28: Challenges in developing T-cell therapies for AML and 2seventy’s solutions
Challenges in developing T-cell therapies for AML and 2seventy’s solutions Aplasia Risk T cell Persistence Challenges in AML Description of issue 2seventy cell therapy solutions AML targets are expressed on healthy myeloid lineage & progenitor cells; aplasia related toxicities are likely to emerge i
Slide 29: PLAT-08: A first-in-human trial of SC-DARIC33
PLAT-08: A first-in-human Phase 1 trial of SC-DARIC33 Primary Aim: Determine the maximum tolerated and biologically effective dose Eligibility: Children and young adults with relapsed/refractory CD33+ AML 29 Link to ClinicalTrials.gov for full study information, including primary and secondary outco
Slide 30: What are we looking for in the early days of this trial
What are we looking for in the early days of this trial 30 Can we dose Rapa to maintain levels within target range for DARIC activation? Does that result in DARIC dimerization, activation and expansion? Do the DARIC cells engage antigen and mediate target cell cytotoxicity? 1 2 3
Slide 31: Can we dose Rapa to maintain levels within target range for DARIC activation?
Can we dose Rapa to maintain levels within target range for DARIC activation? 1 As of March 17, 2023, three patients had received lymphodepletion (LD) and SC-DARIC33 therapy at dose level 1 (1 x 106 SC-DARIC33 T cells/kg). Rapamycin dosing was adjusted by the treating physician to attain target leve
Slide 32: SC-DARIC33 T cells increased in tumor tissue compared to blood
Compared to blood, SC-DARIC33 T cells (VHH+FRB+) were increased among T cells in tumor tissue. Patient S002Do therapeutic Rapa levels result in DARIC dimerization, activation and expansion? 2 32
Slide 33: Progressive hemorrhagic necrosis of the chloromas
Progressive hemorrhagic necrosis of the chloromas Do the DARIC cells engage antigen and mediate target cell cytotoxicity? Chloroma: Two extramedullary leukemic “tumors” in the skin above the eyelid Patient S0023 33
Slide 34: Percentage of lymphocytes that are DARIC cells
Percentage of total lymphocytes that are DARIC cells Percentage of CD3+ T-cells that are “turned on” by Rapa (VHH+FRB+) Patient S004Does therapeutic Rapa levels result in DARIC dimerization, activation and expansion? 2 34
Slide 35: Transient clearance of leukemic blasts in blood
Transient clearance of leukemic blasts in blood Do the DARIC cells engage antigen and mediate target cell cytotoxicity? Patient S0043 35
Slide 36: Summary of initial PLAT-08 correlative data
Summary of initial PLAT-08 correlative data First three patients / Dose Level 1 Initial safety and tolerability data consistent with CAR T cell approaches We can dose RAPA to target levels and turn the system on SC-DARIC33 T cells activate and expand SC-DARIC33 T cells traffic to, engage and kill ta
Slide 37: Our Next-Gen AML program builds on SC-DARIC33 success
Our Next-Gen AML (NG-AML) program builds on SC-DARIC33 success Rapamycin-based CAR regulation 1 Solving for aplasia risk Signaling via the native T Cell Receptor 2 Solving for reduced antigen expression Dual Antigen Targeting 3 Solving for disease heterogeneity Soluble IL-15 for better T cell persis
Slide 38: The NG-AML CAR is tightly controlled by rapamycin dosing
The NG-AML CAR is tightly controlled by rapamycin dosing Rapamycin-based CAR regulation 1 38
Slide 39: Signaling via the native T Cell Receptor
Signaling via the native T Cell Receptor The NG-AML CAR uses the RESET architecture for higher antigen sensitivity The Rapamycin-Enabled, Switchable Endogenous TCR (RESET) architecture demonstrates enhanced sensitivity to low target density limiting low antigen escape 2 39
Slide 40: The NG-AML CAR recognizes CD33 and CLL-1
The NG-AML CAR recognizes CD33 and CLL-1 to address AML heterogeneity ➢ CD33 and CLL-1 have high expression and prevalence in AML blasts and Leukemic Stem Cells (LSCs) ➢ CD33 binder targets the conserved C2 domain AML LSCsAML Bulk C D 33 C L L 1 C D 33 C L L 1 Perna et al, Cancer Cell 2017 Dual Anti
Slide 41: Dual Antigen Targeting
Dual Antigen Targeting The NG-AML CAR recognizes CD33 and CLL-1 to address AML heterogeneity CD33: CLL-1: 3 41 ➢ CD33 and CLL-1 have high expression and prevalence in AML blasts and Leukemic Stem Cells (LSCs) ➢ CD33 binder targets the conserved C2 domain
Slide 42: Soluble IL-15 for better T cell persistence
Soluble IL-15 for better T cell persistence The NG-AML CAR incorporates IL-15, resulting in more potent T cells IL-15 activity is regulated by a T cell activation-dependent synthetic promoter Addition of iSynPro-IL15* improves in vivo AML tumor control 4 42
Slide 43: Our Next-Gen CAR T for AML: Bold and packed with innovations
27T32 27T32 Our Next-Gen CAR T for AML: Bold and packed with innovations Solving reduced antigen expression Novel architecture enhances sensitivity to low target density Regulatable system reduces T cell exhaustion and promotes memory Solving T cell exhaustion Regulatable system reduces risks from l
Slide 44: Ex Vivo and In Vivo Gene Editing Applications
Ex Vivo and In Vivo Gene Editing Applications 44 Mike Certo, Ph.D., VP, head of genome editing
Slide 45: megaTAL Platform: Engineering activity and specificity
megaTAL Platform: Engineering activity and specificity 45 Gene Editing Architecture megaTAL attributes Protein Engineering for Activity and Specificity TAL Array Anchor Meganuclease Binding Meganuclease Cleavage 10-12 bp TAL target recognition 22 bp MN target recognition Creates a 4 bp, 3’ overhang
Slide 46: Gene Editing Ex Vivo vs In Vivo
Gene Editing Ex Vivo vs In Vivo 46 Ex Vivo In Vivo 2 1 3 4 Extract cell Collect blood Grow culture Engineer cells through viral or nonviral methods 4 Re-introduce modified cells 1 Direct delivery using viral or non-viral vehicle Viral delivery Adeno Associated Virus (AAV) Non-viral delivery Lipid na
Slide 47: Gene Editing Ex Vivo vs In Vivo
Gene Editing Ex Vivo vs In Vivo 47 Ex Vivo In Vivo 2 1 3 4 Extract cell Collect blood Grow culture Engineer cells through viral or nonviral methods 4 Re-introduce modified cells 1 Direct delivery using viral or non-viral vehicle Viral delivery Adeno Associated Virus (AAV) Non-viral delivery Lipid na
Slide 48: bbT369: Autologous CAR T product purpose-built for need in b-NHL
bbT369: Autologous CAR T product purpose-built to address significant need in b-NHL 48 Challenges in bNHL CAR T Description of issue CD19 Loss Target-Antigen Downregulation Poor outcomes in patients with Challenging TME and/or Aggressive disease ~30% of CD19 CAR T relapse patients have CD19 negative
Slide 49: ASGCT data on CBLB edit maintaining CAR T activity
Data presented at ASGCT demonstrate potential of the CBLB edit to maintain CAR T activity across multiple challenging tumor scenarios 49
Slide 50: CRC-403 study in B-NHL open and enrolling
CRC-403 study in B-NHL open and enrolling CRC-403: A Phase 1/2 Study of bbT369 in Relapsed and/or Refractory B-Cell Non-Hodgkin Lymphoma (B-NHL) QUESTIONS Is the safety and tolerability of bbT369 in line with prior CAR Ts? Does bbT369 show anti-B cell activity in R/R B-NHL patients? Does bbT369 show
Slide 51: Gene Editing Ex Vivo vs In Vivo
Gene Editing Ex Vivo vs In Vivo 51 Ex Vivo In Vivo 2 1 3 4 Extract cell Collect blood Grow culture Engineer cells through viral or nonviral methods Re-introduce modified cells 1 Direct delivery using viral or non-viral vehicle Viral delivery Adeno Associated Virus (AAV) Non-viral delivery Lipid nano
Slide 52: Gene Editing Ex Vivo vs In Vivo
Gene Editing Ex Vivo vs In Vivo 52 Ex Vivo In Vivo 2 1 3 4 Extract cell Collect blood Grow culture Engineer cells through viral or nonviral methods 4 Re-introduce modified cells 1 Direct delivery using viral or non-viral vehicle Viral delivery Adeno Associated Virus (AAV) Non-viral delivery Lipid na
Slide 53: Hemophilia A
Hemophilia A Severe and debilitating genetic bleeding disease caused by the absence of the critical clotting molecule Factor VIII 53 Phenotypes Therapies BRUISING that can lead to hematoma SPONTANEOUS INTERNAL BLEEDING which can be life threatening if in vital organs EXCESSIVE BLEEDING following inj
Slide 54: Addresses gaps in SOC and AAV only Hem A approaches
Addresses gaps in SOC and AAV Only Hem A approaches 54 DURABLE expression without activity Troughs AAV Episomal transgene expression declines, cannot be redosed and not suitable for Pediatrics i.v. FVIII ERT requires repeat dosing and has deep troughs – acute bleeds and joint deterioration over time
Slide 55: In Vivo Gene Therapy for Hemophilia A
Direct delivery using viral or non-viral vehicle In Vivo Gene Therapy for Hemophilia A Product concept In Vivo Gene Therapy Non-viral delivery Lipid nanoparticle (LNP) Viral delivery Adeno Associated Virus (AAV) 55 Development Responsibilities in partnership with Potentially lifelong correction of F
Slide 56: 2seventy & Novo Nordisk Collaboration Overview
Complimentary co-creation partnership to bring next-generation Hemophilia therapies to patients: Built around shared vision and transformational science Leveraging 2seventy’s gene therapy expertise and Novo’s deep clinical experience in hemophilia 2seventy & Novo Nordisk Collaboration Overview Resea
Slide 57: Delivering best-in-class liver knock-in approaches for Hemophilia A
megaTAL mRNA LNP Vector Genome Capsid Delivering best-in-class liver knock-in approaches for Hemophilia A Scientific Considerations 57 LNP/megaTAL - mRNA AAV-Transgene
Slide 58: Exploring Product Component Designs
Exploring Product Component Designs megaTAL Enzyme mRNA LNP Formulations AAV - genome mRNA concentration % IN D E L mRNA concentration % I N D E L % Integration F V II I a n ti g e n LNP1 LNP2 T a rg e t P ro te in ( n g /m g ) Gen 2 Gen 1 Gen 2 Gen 1 Gen 2 Gen 1 Gen 2 Gen 1 58
Slide 59: In vivo gene editing PoC for FVIII expression
In vivo gene editing PoC for FVIII expression*In vivo gene editing PoC for FVIII expression Mouse proof-of-concept Bleed normalization Key Characteristics of the preclinical study P B S A A V-N 8 + L N P -m eg aT AL P os iti ve c trl 0 25 50 75 100 % o f n o rm a l P B S A A V-N 8 + L N P -m eg aT A
Slide 60: Novo Nordisk collaboration: preclinical milestone triggered
“Novo Nordisk is proud to work in such close and creative collaboration with the team at 2seventy. We are thrilled this program has achieved the strong proof of concept data, triggering this important milestone event.” – Marcus Schindler, Executive vice president research and early development, and
Slide 61: Development Considerations
D ev el o p m en t C o n si d er at io n s In vivo gene editing approaches potential platform expansion Same approach used for Heme A allows leveraging existing megaTAL, LNP, and AAV improvements POC with the Hem A program provides a development path. Simpler LNP/mRNA only drug product Leverage LNP
Slide 62: Summary
Summary 62 Clinical progress with SC-DARIC33 in patients with AML 2seventy bio’s NextGen AML approach…. packed with innovation First regulatable CAR T cell data from the clinical trial* Key questions addressed: • Initial safety and tolerability in line with CAR T cell approaches • We can dose RAPA t
Slide 63: 2seventy bio’s R&D philosophy
2seventy bio’s R&D philosophy 63 Accelerate with Industry Leading Partnerships Identify the Key Problem Layer Innovations Learn Fast in the Clinic Understand tumor resistance Explore new biology Focus on the hard problem Define clear hypotheses Deploy our unique toolbox Deliver multi-nodal solutions
Slide 64: Q&A
Q&A